Abbott Laboratories Corporation

Abbvie Inc.

E.i. Dupont De Nemours and Company

Abbvie Deutschland Gmbh and Co Kg

The Dupont Merck Pharmaceutical Company

Calico Life Sciences LLC

Abbvie Bahamas Limited

Lawrence A Black

Marlon D Cowart

Huaqing Liu

Robert J Altenbach

Gregory A Gfesser

Anwer Basha

Chen Zhao

Youssef L Bennani

Ramin Faghih

Brian D Wakefield

William L Matier

Joseph F Dellaria, Jr

David M Stout

Wendy Lee

Irene I Drizin

Sou-Jen Chang

Linda J Chernesky

Robert J Gregg

Gin C Hsieh

Charles W Hutchins

Karla Drescher

Sean Colm Turner

Michael J Dart

Berthold Behl

Teodozyj Kolasa

Michael Ochse

Andrew O Stewart

Jennifer M Frost

Hervé Geneste

Meena V Patel

Yi-Yin Ku

Michael E Kort

Jeffrey J Rohde

Lei Shi

Yunsong Tong

Marina Pliushchev

Kirill A Lukin

Ramzi Farah Sweis

Diana L Nersesian

Michael P Curtis

Yu-Ming M Pu

Qingwei I Zhang

Xiangdong Xu

Michael J Coghlan

Catherine M McCarty

Seungwon Chung

Yu-Ming Pu

Guo Zhu Zheng

John R Koenig

Minghua Sun

Katja Jantos

Lawrence Kolaczkowski

Neil Wishart

Jürgen Dinges

Padam N Sharma

Clarissa Jakob

Loic Laplanche

Jorge D Brioni

Marie P Honore

Timothy A Esbenshade

David J Babinski

Arthur A Hancock

Anthony Ralph Haight

Geoff G Z Zhang

Anil Vasudevan

Rodger F Henry

David M Barnes

Ahmad Y Sheikh

Steven J Wittenberger

Kennan C Marsh

Paul J Brackemeyer

Henry Q Zhang

Xiaochun Lou

Wesley J Dwight

Michael G Fickes

Robert Gentles

Carmela Sidrauski

Kathryn J Hancock, Legal Representative

Kathleen M Phelan

Linda J Dorn

Jae Y Lee

Maria G Beconi

Jill M Wetter

Thomas C Custer

Jill Wetter

Zhenping Tian

Ramzi Farath Sweis

Marina Pliuschev

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Modulators of the integrated stress pathway

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

Inhibitor compounds of phosphodiesterase type 10A

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.  

Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors

The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X, X, X, Rand Rare defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 

Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A

Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Radiolabeled PDE10A ligands

Compounds of formula (I) wherein R, R, R, R, R, R, and Rare defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Cyclopropyl amine derivatives

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Compounds of the formula wherein Rand Rare as disclosed herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor full or partial agonists. Also disclosed are pharmaceutical compositions, methods for using such compounds and compositions, and processes for preparing the compounds.

4-substituted-2-amino-pyrimidine derivatives

Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.

Macrocyclic benzofused pyrimidine derivatives

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Benzothiazole and benzooxazole derivatives and methods of use

Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic pyrimidine derivatives

Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Octahydro-pyrrolo[3,4-B]pyrrole derivatives

Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic spiro pyrimidine derivatives

Growing community of inventors

Libertyville, IL, United States of America

Lawrence A Black